NCT00495053View on ClinicalTrials.gov

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

PHASE1TerminatedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

November 30, 2009

Conditions

Overactive Bladder

Interventions

DRUG

hMaxi-K

Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)

OTHER

Placebo

Matching placebo (PBS-20% sucrose)

Trial Locations (1)

06405

CE3, Inc., Branford

Sponsors

Collaborators (1)

Ion Channel Innovations

All Listed Sponsors

collaborator

Ion Channel Innovations

INDUSTRY

lead

Urovant Sciences GmbH

INDUSTRY